Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sarepta Therapeutics, Inc. (SRPT : NSDQ)
 
 • Company Description   
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.

Number of Employees: 840

 
 • Price / Volume Information   
Yesterday's Closing Price: $71.13 Daily Weekly Monthly
20 Day Moving Average: 806,639 shares
Shares Outstanding: 87.50 (millions)
Market Capitalization: $6,223.94 (millions)
Beta: 1.29
52 Week High: $101.24
52 Week Low: $61.28
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.90% 1.94%
12 Week -6.44% 5.14%
Year To Date -21.01% -3.50%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
215 FIRST STREET SUITE 415
-
CAMBRIDGE,MA 02142
USA
ph: 617-274-4000
fax: 425-354-5038
iestepan@sarepta.com http://www.sarepta.com
 
 • General Corporate Information   
Officers
Douglas S. Ingram - Chief Executive Officer and President
M. Kathleen Behrens - Chairman
Ian M. Estepan - Executive Vice President; Chief Financial Officer
Richard Barry - Director
Stephen L. Mayo - Director

Peer Information
Sarepta Therapeutics, Inc. (CORR.)
Sarepta Therapeutics, Inc. (RSPI)
Sarepta Therapeutics, Inc. (CGXP)
Sarepta Therapeutics, Inc. (BGEN)
Sarepta Therapeutics, Inc. (GTBP)
Sarepta Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 803607100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 87.50
Most Recent Split Date: 7.00 (0.17:1)
Beta: 1.29
Market Capitalization: $6,223.94 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.12 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.53 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 7.26
Price/Cash Flow: -
Price / Sales: 8.13
EPS Growth
vs. Year Ago Period: 42.86%
vs. Previous Quarter: 15.49%
Sales Growth
vs. Year Ago Period: 43.49%
vs. Previous Quarter: 4.65%
ROE
03/31/22 - -52.06
12/31/21 - -69.28
09/30/21 - -86.35
ROA
03/31/22 - -12.27
12/31/21 - -14.78
09/30/21 - -17.41
Current Ratio
03/31/22 - 5.56
12/31/21 - 5.75
09/30/21 - 5.85
Quick Ratio
03/31/22 - 5.13
12/31/21 - 5.34
09/30/21 - 5.08
Operating Margin
03/31/22 - -46.56
12/31/21 - -59.67
09/30/21 - -75.30
Net Margin
03/31/22 - -46.56
12/31/21 - -59.67
09/30/21 - -75.30
Pre-Tax Margin
03/31/22 - -46.45
12/31/21 - -59.69
09/30/21 - -75.21
Book Value
03/31/22 - 9.79
12/31/21 - 10.66
09/30/21 - 5.39
Inventory Turnover
03/31/22 - 0.45
12/31/21 - 0.39
09/30/21 - 0.34
Debt-to-Equity
03/31/22 - 1.28
12/31/21 - 1.18
09/30/21 - 2.33
Debt-to-Capital
03/31/22 - 56.19
12/31/21 - 54.17
09/30/21 - 69.99
 

Powered by Zacks Investment Research ©